Testing a maintenance medication after chemotherapy for advanced ovarian cancer

Plain-English translation of NCT06141265 on ClinicalTrials.gov ↗ · Source last updated October 2026 · Translation generated July 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This trial is testing , a medication designed to help prevent ovarian cancer from coming back after chemotherapy. You would take this medication daily by mouth after you have completed your initial chemotherapy combined with bevacizumab. The study wants to see how well this treatment works and is safe for women whose cancer has specific genetic changes that make it more likely to respond to this type of medication.

After chemotherapy, ovarian cancer often comes back. Doctors want to find ways to keep the cancer from returning for as long as possible. This medication has shown promise in other studies, and researchers believe it may help prevent recurrence in patients whose tumors have certain genetic features.

Do you qualify?

You likely qualify if…

you are 18 years or older and female
you have been diagnosed with advanced ovarian, fallopian tube, or primary peritoneal cancer (stage III or IV)
you have had surgery to remove your cancer and have received at least 2 cycles of chemotherapy combined with bevacizumab
your cancer has responded well to chemotherapy (no evidence of disease, partial response, or complete response)
your tumor has tested positive for HRD (homologous recombination deficiency) or a BRCA mutation
your blood counts and organ function are in acceptable ranges and you are in reasonably good health overall

You likely don't qualify if…

you have ovarian cancer that is not high-grade or you have cancer that has spread to your ovaries from another organ
you have serious heart, lung, or blood disorders, or uncontrolled high blood pressure or diabetes
you are currently taking other targeted cancer drugs as maintenance therapy
you have been diagnosed with another type of cancer in the past 2 years and are still being treated for it
your doctor believes you are unlikely to survive longer than 3 months

What participation looks like

You would take as a daily oral tablet for an extended period following your chemotherapy treatment. The starting dose would be 300 mg or 200 mg per day, depending on your body weight and blood cell counts. You would have regular follow-up visits with your cancer care team to monitor how well the medication is working, check for any side effects, and conduct blood tests and imaging scans to track your cancer.

AI-generated summary from trial data · Jul 21, 2026 · Not medical advice

Trial locations(1 site)

China

Peking University Cancer Hospital, Beijing, Beijing Municipality